Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Aspire-Lakewood HoldingsASBP +2.42%11 EV-to-EBIT is -4.85 as of Sep. 11, 2026. GuruFocus rates ASBP with a GF Score™ of 11/100. The stock has 2 warning signs investors should review. Among 366 Biotechnology companies, Aspire-Lakewood Holdings ranks worse than 273223.77% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Aspire-Lakewood Holdings's Enterprise Value for the quarter that ended in Jun. 2026 was $-5.25 Mil.
Aspire-Lakewood Holdings's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.74 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aspire-Lakewood Holdings EV-to-EBIT Related Terms
Aspire-Lakewood Holdings EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Aspire-Lakewood Holdings's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aspire-Lakewood Holdings EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Aspire-Lakewood Holdings's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Aspire-Lakewood Holdings's EV-to-EBIT falls into.
Aspire-Lakewood Holdings's current Enterprise Value is $8.43 Mil.
Aspire-Lakewood Holdings's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.74 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aspire-Lakewood Holdings (ASBP) has a EV-to-EBIT of -4.85 as of Sep. 11, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Aspire-Lakewood Holdings and its competitors. According to the industry distribution chart, Aspire-Lakewood Holdings ranks #999999 out of 366 companies in the Biotechnology industry.
Is Aspire-Lakewood Holdings' EV-to-EBIT too high?
Aspire-Lakewood Holdings' current EV-to-EBIT is -4.85. Based on the distribution chart, Aspire-Lakewood Holdings ranks #999999 out of 366 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Aspire-Lakewood Holdings has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Aspire-Lakewood Holdings' EV-to-EBIT compare to PDSB and KPRX?
According to the Biotechnology industry distribution chart, Aspire-Lakewood Holdings ranks #999999 out of 366 companies for EV-to-EBIT. This places Aspire-Lakewood Holdings in the lower half of its industry. The industry median EV-to-EBIT is 15.59. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 15.59, based on 366 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Aspire-Lakewood Holdings and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 15.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aspire-Lakewood Holdings's current EV-to-EBIT is -4.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aspire-Lakewood Holdings stock overvalued right now?
Aspire-Lakewood Holdings (ASBP) has a current EV-to-EBIT of -4.85. The current EV-to-EBIT is -4.85. Aspire-Lakewood Holdings' overall GF Score™ is 11/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Aspire-Lakewood Holdings (ASBP), the current EV-to-EBIT is -4.85 as of Sep. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Aspire Biopharma Holdings Inc is an early-stage biopharmaceutical company focused on developing and commercializing novel sublingual drug delivery technologies. The company is mainly engaged in advancing patent-pending formulations designed to enable rapid absorption of drugs, initially targeting high-dose aspirin products for cardiovascular and pain management applications. Its technology aims to improve efficacy and response time by bypassing the gastrointestinal tract through sublingual delivery.
11GF Score
Get the complete analysis for ASBP
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASBP has been successfully added to your 
